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in trial 1 and 6% in trial 2, and total 100-day treatment-related
mortality was 13% in trial 1 and 6% in trial 2. The incidence of
chronic GVHD in the 2 trials was 49% and 44%, respectively. At
2 years, the relapse-free and overall survival estimates for trial 1 are
46% and 48%, respectively (median follow-up, 27 months). One
year relapse-free and overall survival estimates for trial 2 are 71%
and 75%, respectively (median follow-up, 11 months). Overall
survival at 2 years is 72%. Conclusions: Sirolimus, when added to
tacrolimus after allogeneic stem cell transplantation, is effective as
GVHD prophylaxis. Engraftment is prompt, and transplant-re-
lated morbidity and mortality is reduced. Survival estimates are
excellent due to reduced GVHD and transplant-related toxicity.
Sirolimus is worthy of broader study in allogeneic transplantation.
10
SIROLIMUS AND THROMBOTIC MICROANGIOPATHY AFTER ALLOGE-
NEIC STEM CELL TRANSPLANTATION
Cutler, C.; Henry, N.L.; Li, S.; Kim, H.T.; Magee, C.; Alyea, E.; Ho,
V.; Soiffer, R.; Antin, J. Dana Farber Cancer Institute and Brigham
and Women’s Hospital, Harvard Medical School, Boston, MA.
Sirolimus (SRL) is a novel immunosuppressive agent that can
reduce GVHD and minimize morbidity after allogeneic stem cell
transplantation (SCT). Thrombotic microangiopathy (TMA) is
characterized by microangiopathic hemolysis, thrombocytopenia,
and renal dysfunction and is associated with calcineurin inhibitors
(CIs). To determine whether SRL use potentiates the effects of CIs
on TMA incidence and risk factors, we performed a retrospective
cohort analysis of subjects who underwent SCT between 1997 and
2003. Methods: Subjects who received a SRL-containing GVHD
prophylaxis regimen were compared with a cohort who received a
non-SRL regimen. All subjects received CIs. Diagnosis of TMA
required the simultaneous occurrence of (1) creatinine elevation 
2 mg/dl or  50% above baseline, (2) schistocytosis, (3) elevated
LDH, and (4) no evidence of DIC. Results: The 111 patients who
received SRL were compared with 216 patients who received no
SRL. The 2 groups of patients were balanced for demographic
parameters; however, more patients in the SRL group received
PBSC transplants (50.5 vs 18.1%; P  .01) and had unrelated
donors (58.6 vs 42.6%, P  .01). The incidence of TMA was
higher in the SRL group than in the non-SRL group (10.8% vs
4.2%; OR  2.57, P  .03). SRL patients developed TMA earlier
than did non-SRL patients (median, 25 days vs 58 days; P  .04).
At TMA diagnosis, median blood levels of immunosuppressive
medications were all within their respective therapeutic ranges. In
a multivariable logistic regression model, only the use of SRL
(adjusted exact OR  3.49, P  .02) and grade II-IV acute GVHD
(adjusted exact OR  6.60, P  .0002) predicted the occurrence of
TMA. Treatment of TMA consisted of discontinuation or dose
adjustment of CIs and SRL. Two subjects in each group required
temporary hemodialysis, and 3 subjects (1 SRL, 2 non-SRL) un-
derwent plasmapheresis. A total of 78% of surviving SRL-treated
subjects regained normal renal function. No subject had a TMA
recurrence if SRL was reintroduced. CIs were never reintroduced.
Overall survival after TMA diagnosis was better for SRL patients
than for non-SRL patients (58.3% vs 11.1%; log rank P  .02).
Conclusion: SRL is associated with an increased risk of TMA after
SCT and may act by potentiating the effects of CIs. TMA associ-
ated with SRL appears to be reversible and does not affect overall
survival after SCT. A careful monitoring strategy for TMA should
be used as part of a SRL-containing GVHD prophylaxis regimen.
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PALIFERMIN (A RHUKGF MOLECULE) IS SAFE AND WELL TOLERATED
IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES (HM) UNDERGO-
ING HIGH-DOSE CHEMORADIOTHERAPY (HD-CRT) FOLLOWED BY AL-
LOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
Blazar, B.R.1; Weisdorf, D.J.1; DeFor, T.E.1; Goldman, A.I.1; Silver,
S.2; Ferrara, J.L.M.2 1. University of Minnesota, Minneapolis, MN; 2.
University of Michigan, Ann Arbor, MI.
The major limitation of allogeneic HSCT is graft-versus-host-
disease (GVHD), a complication where the skin, gastrointestinal
(GI) tract, and liver are damaged by cytokine effectors. Palifermin
has a growth-enhancing differentiation and cytoprotective effect in
the oral and GI mucosa and may be useful as a GVHD prophylaxis.
Previously, we demonstrated that palifermin signiﬁcantly reduced
the incidence, duration, and severity of oral mucositis (OM) in the
autologous HSCT setting. Two animal studies demonstrated pali-
fermin could prevent mucositis and GVHD after CRT. In this
investigator-initiated, randomized, double-blind, placebo-con-
trolled, dose-escalation trial, the safety of palifermin administra-
tion to HM patients undergoing HD-CRT following by allogeneic
HSCT was evaluated. Methods: Patients were entered into 1 of 3
sequentially-enrolled dose/schedule cohorts involving administra-
tion of study drug (placebo or palifermin) on days 11, 10, 9,
0, 1, and 2 relative to HSCT (day 0). Three additional doses were
given to each sequential cohort: stage 1 (3 pretreatment/3 post-
treatment), stage 2 (3 pretreatment/6 posttreatment), or stage 3 (3
pretreatment/9 posttreatment). Adverse events (AEs) were col-
lected continuously. Patients were followed for safety for 100 days
and for survival/relapse for 1 year. Results: A total of 100 patients
(31 placebo, 69 palifermin [8 receiving 40 g/kg/day and 61 re-
ceiving 60 g/kg/day]) were randomized to stage 1, 2, or 3. Time
to engraftment for ANC and platelets was similar between treat-
ment groups. No signiﬁcant differences in the incidence or severity
of GVHD, survival, or relapse rates were observed between treat-
ment groups. Overall, 20 patients (2 placebo, 18 palifermin) dis-
continued the study. Of these, 6 patients (2 placebo, 4 palifermin)
experienced a total of 11 dose-limiting toxicities (DLTs). Discon-
tinuations and DLTs were most common in patients who received
at least 6 doses of study drug after engraftment (day 0). Eighteen
patients (5 placebo, 13 palifermin) died before day 100, due pri-
marily to treatment complications. Palifermin appeared to have a
beneﬁcial effect on OM, but no effect was observed on diarrhea.
Conclusion: Palifermin administration in the allogeneic treatment
setting was safe and well tolerated and did not have any negative
effects on engraftment, GVHD, or survival rates.
12
ADOPTIVE TRANSFER OF IN VITRO-GENERATED T CELL PRECURSORS
ENHANCES POSTTRANSPLANT DONOR T CELL RECONSTITUTION IN
RECIPIENTS OF AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
Zakrzewski, J.L.1; Kochman, A.1; Muriglan, S.J.1; Lu, S.1; Kim,
T.D.1; Zuniga-Pﬂucker, J.C.2; Alpdogan, O.1; van den Brink, M.R.M.1
1. Memorial Sloan Kettering Cancer Center, New York, NY; 2. Sun-
nybrook and Women’s College Health Sciences Centre, University of
Toronto, Toronto, ON, Canada.
Recent studies have shown that murine T cells and their precur-
sors can be generated from hematopoietic stem cells (HSC) in vitro
using a novel OP9-DL1 co-culture system consisting of OP9 bone
marrow stromal cells expressing Delta-like 1 Notch ligand (which
binds to the Notch 1 receptor) and growth factors (interleukin 7
and fms-like tyrosine kinase-3 ligand). In this study we determined
the effects of ex vivo-generated T cell precursors on T cell recon-
stitution after allo HSCT. We selected Lin-, Sca-1hi, and c-kithi
HSC from donor bone marrow and cultured these on a monolayer
of OP9-DL1 cells in the presence of growth factors. These
HSC expanded 850-5000-fold and consisted of 95% CD4-CD8
double-negative (DN) T cell precursors after 16–28 days of
culture. We infused these cells (8  106) with T-cell- depleted
(TCD) BM (5  106) into allogeneic recipients. Control mice
received TCD BM only. To determine the effects on T cell
reconstitution after allo HSCT we analyzed thymi and spleens
at days 14 and 29 after transplant by ﬂow cytometry. Progeny
of OP9-DL1 T cell precursors was found on days 14 and 29 in
both thymus and spleen, including 40% (	 20%) of thymo-
cytes and 25% (	 9%) of splenic T cells on day 14 posttrans-
plant and 3.6% (	 2.4%) of thymocytes and 33% (	 7%) of
splenic T cells on day 29 posttransplant. The thymic cellularity was
increased up to 50% on day 14 posttransplant in the OP9-DL1
HSCT group compared to the control group. Splenic T cell
numbers were not increased in OP9-DL1 recipients; however,
donor T cell chimerism was enhanced signiﬁcantly 88.5% vs 65%).
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